Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective

被引:18
作者
Cubbon, R. [1 ]
Kahn, M. [1 ]
Kearney, M. T. [1 ]
机构
[1] Univ Leeds, Cardiovasc & Diabet Res Grp, Leeds Inst Genet Hlth & Therapeut, Leeds LS2 9JT, W Yorkshire, England
关键词
D O I
10.1111/j.1742-1241.2007.01646.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with type 2 diabetes mellitus (T2DM) and prediabetes have a substantially greater risk of developing cardiovascular (CV) disease than the general population. This increased risk of CV disease is due to a complex cluster of risk factors including insulin resistance, hyperglycaemia, diabetic dyslipidaemia, hypertension and systemic inflammation. As a result of this cluster of risk factors, life expectancy is reduced by up to 10 years upon diagnosis of T2DM, principally because of fatal CV events. Patients with T2DM are not only more likely to sustain a CV event, but also have a higher risk of a fatal outcome from this event. Therefore, whilst primary prevention is critical in determining the prognosis of patients newly diagnosed with T2DM, many will go on to suffer CV events and represent a high-risk group requiring intensive secondary prevention techniques. Recent data demonstrate that contemporary prevention therapies do not afford equal benefits to T2DM sufferers after acute myocardial infarction compared with their non-diabetic counterparts. This finding highlights the need for more effective secondary preventative strategies to prevent recurrent CV events in patients with T2DM and prediabetes. The cardiologist's role in the multidisciplinary management of T2DM is to improve patient outcomes by optimising use of evidence-based strategies for the prevention of recurrent CV events.
引用
收藏
页码:287 / 299
页数:13
相关论文
共 124 条
[1]   Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients - Insights from the Arterial Revascularization Therapy Study (ARTS) trial [J].
Abizaid, A ;
Costa, MA ;
Centemero, M ;
Abizaid, AS ;
Legrand, VMG ;
Limet, RV ;
Schuler, G ;
Mohr, FW ;
Lindeboom, W ;
Sousa, AGMR ;
Sousa, JE ;
van Hout, B ;
Hugenholtz, PG ;
Unger, F ;
Serruys, PW .
CIRCULATION, 2001, 104 (05) :533-538
[2]  
*ADDITION STUD, INT TREATM COMPL PRE
[3]   The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure [J].
Aguilar, David ;
Bozkurt, Biykern ;
Pritchett, Allison ;
Petersen, Nancy J. ;
Deswal, Anita .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (01) :32-36
[4]   The metabolic syndrome - a new worldwide definition [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
LANCET, 2005, 366 (9491) :1059-1062
[5]  
Alderman EL, 2000, J AM COLL CARDIOL, V35, P1122
[6]   Long-term weight maintenance after an intensive weight-loss program [J].
Anderson, JW ;
Vichitbandra, S ;
Qian, W ;
Kryscio, RJ .
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 1999, 18 (06) :620-627
[7]   Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment [J].
Angiolillo, DJ ;
Fernandez-Ortiz, A ;
Bernardo, E ;
Ramírez, C ;
Sabaté, M ;
Jimenez-Quevedo, P ;
Hernández, R ;
Moreno, R ;
Escaned, J ;
Alfonso, F ;
Bañuelos, C ;
Costa, MA ;
Bass, TA ;
Macaya, C .
DIABETES, 2005, 54 (08) :2430-2435
[8]  
[Anonymous], 1990, METABOLISM, V39, P905, DOI 10.1016/0026-0495(90)90299-R
[9]  
[Anonymous], STUD CARD EV DIAB
[10]  
[Anonymous], Study of the Effectiveness of Response to Intervention Used